Over the course of the past decade, critics have increasingly called attention to the corrosive influence of the pharmaceutical industry on both biomedical research and the practice of medicine. Critics describe the industry's use of ghostwriting and other unethical techniques to expand their markets as evidence that medical science is all-too-frequently subordinated to the goals of corporate profit. While we do not dispute this perspective, we argue that it is imperative to also recognize that the goals of medical science and industry profit are now tightly wed to one another. As a result, medical science now operates to expand disease definitions, lower diagnostic thresholds, and otherwise advance the goals of corporate profit through the redefinition and expansion of what it means to be ill. We suggest that this process has led to a variety of ethical problems that are not fully captured by current critiques of ghostwriting and other troubling practices by the pharmaceutical industry. In our conclusion, we call for physicians, ethicists, and other concerned observers to embrace a more fundamental critique of the relationship between biomedical science and corporate profit.
ThomasK., and SchmidtM. S.Glaxo agrees to pay $3 billion in fraud settlement. The New York Times, July 2, 2012.
3.
U.S. Government. U.S.C. 21 §§ 301–97.
4.
NemeroffC. B.Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch. Gen. Psychiatry.64: 466–472, 2007.
5.
LeeE.Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol. Drug Saf. 21: 137–144, 2012.
6.
SismondoS.Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry?PLoS Med. 4: e286, 2007.
7.
LacasseJ. R.Knowledge of undisclosed corporate authorship (“ghostwriting”) reduces the perceived credibility of antidepressant research: A randomized vignette study with experienced nurses. BMC Res. Notes.4: 27, 2011.
8.
SternS., and LemmensT.Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles. PLoS Med. 8(8): e1001070, 2011.
9.
SismondoS.Ghosts in the machine: Publication planning in the medical sciences. Soc. Stud. Sci.39: 171–198, 2009.
10.
LacasseJ. R., and LeoJ.Ghostwriting at elite academic medical centers in the United States. PLOS Med. 7(2): e1000230, 2010.
11.
RodwinM. A.Rooting out institutional corruption to manage inappropriate off-label drug use. J. Law Med. Ethics.41: 654–664, 2013.
12.
HerperM.A former pharma ghost writer speaks out. www.forbes.com, August 10, 2011.
13.
BrodyH. T.Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Rowman & Littlefield, Hagerstown, 2007.
14.
ElliotC.White Coat, Black Hat: Adventures on the Dark Side of Medicine. Beacon Press, Boston, 2010.
15.
EatonL.Medical editors issue guidance on ghost writing. BMJ330: 988, 2005.
16.
EpsteinS.Impure Science: AIDS, Activism, and the Politics of Knowledge. University of California, Berkeley, 1998.
17.
WailooK.Drawing Blood: Technology and Disease Identity in Twentieth-Century America. Johns Hopkins University, Baltimore, 2009.
18.
RoseN.The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton University, Princeton, 2006.
19.
GreeneJ.Prescribing by Numbers: Drugs and the Definition of Disease. Johns Hopkins University, Baltimore, 2007.
20.
IllichI.Medical Nemesis: The Expropriation of Health. Pantheon Books, New York, 1976.
21.
MoynihanR., and HenryD.The fight against disease mongering: Generating knowledge for action. PLoS Med. 3(4): e191, 2006.
22.
LexchinJ.Bigger and better: How Pfizer redefined erectile dysfunction. PLoS Med. 3(4): e132, 2006.
ApplbaumK.Pharmaceutical marketing and the invention of the medical consumer. PLoS Med. 3(4): e189, 2006.
25.
PayerL.Disease-Mongers: How Doctors, Drug Companies, and Insurers are Making You Feel Sick. John Wiley & Sons, New York, 1994.
26.
DeGrandpreR. J.Ritalin Nation: Rapid-Fire Culture and the Transformation of Human Consciousness. W. W. Norton, New York, 2000.
27.
WilliamsS. J.GabeJ., and DavisP.Pharmaceuticals and Society: Critical Discourses and Debates. Wiley-Blackwell, New York, 2009.
28.
MoynihanR., and CasselsA.Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All Into Patients. Nation Books, New York, 2006.
29.
MosterdA.Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N. Engl. J. Med.340: 1221–1227, 1999.
30.
WilliamsS. J.Waking up to sleepiness: Modafinil, the media and the pharmaceuticalisation of everyday/night life. Sociol. Health Illn. 30: 839–855, 2008.
31.
HorowitzA., and WakefieldJ.The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford, New York, 2007.
32.
BrodyH., and LightD. W.The inverse benefit law: How drug marketing undermines patient safety and public health. Am. J. Pub. Health.101: 399–404, 2011.
33.
StoningtonS.HolmesS. M., and PLoS Medicine Editors. Social medicine in the twenty-first century. PLoS Med. 3(10): e445, 2006.
34.
GoldbergD. S.Social justice, health inequalities, and methodological individualism in U.S. health promotion. Public Health Ethics5: 104–115, 2012.
CapewellS., and GrahamH.Will cardiovascular disease prevention widen health inequalities?PLoS Med. 7(8): e1000320, 2010.
37.
GoldbergD. S.Global health care is not global health: Populations, inequities, and law as a social determinant of health. In The Globalization of Health Care, ed. GlennCohen I.. Oxford, New York, 2013.
38.
Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on Social Determinants of Health. World Health Organization, Geneva, 2008.
39.
FairchildA. L.The EXODUS of public health. What history can tell us about the future. Am. J. Pub. Health.100: 54–63, 2010.
40.
PetrynaA.When Experiments Travel: Clinical Trials and the Global Search for Human Subjects. Princeton University, Princeton, 2009.
41.
WendlerD.EmanuelE. J., and LieR. K.The standard of care debate: Can research in developing countries be both ethical and responsive to those countries' health needs?Am. J. Pub. Health.94: 923–928, 2004.
42.
BayerR.The debate over maternal-fetal HIV transmission prevention trials in Africa, Asia, and the Caribbean: Racist exploitation or exploitation of racism?Am. J. Pub. Health.88: 567–570, 1998.
43.
LondonA. J.Justice and the human development approach to international research. Hastings Cent. Rep.35: 24–37, 2005.
44.
NavarroV.The world health situation. In Neoliberalism, Globalization, and Inequalities: Consequences for Health and Quality of Life, ed. NavarroV.. Baywood Publishing, Amityville, NY, 2007.
45.
AzetsopJ.New directions in African bioethics: Ways of including public health concerns in the bioethics agenda. Dev. World Bioeth. 11: 4–15, 2011.
46.
SkrabenekP.The Death of Humane Medicine and the Rise of Coercive Healthism. Social Affairs Unit, London, 1994.
47.
RoseN.Powers of Freedom: Reframing Political Thought. Cambridge University, New York, 1999.
48.
MetzlJ., and KirklandA. (eds.). Against Health: How Health Became the New Morality. New York University, New York, 2010.
49.
ConradP.The Medicalization of Society. Johns Hopkins University Press, Baltimore, 2007.
50.
BellS., and FigertA. E.Medicalization and pharmaceuticalization at the intersections: Looking backward, sideways and forward. Soc. Sci. Med.75: 775–783, 2012.
51.
GoldbergD.Intervening at the right point in the causal pathways: Law, policy, and the devastating impact of pain across the globe. Ann. Health Law22(2): 198–223, 2013.
52.
RoseG.The Strategy of Preventive Medicine. Oxford University Press, New York, 1992.
53.
PuskaP., and StahlT.Health in All Policies—The Finnish initiative: Background, principles, and current issues. Ann. Rev. Pub. Health.31: 315–328, 2010.
